{"gene":"HDGF","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2005,"finding":"The HDGF PWWP domain (N-terminal ~70 amino acids) was determined to high resolution by NMR using NOEs, J-couplings, and dipolar couplings. NMR titrations and SELEX (SAAB) assays demonstrated that the PWWP domain functions as a nonspecific DNA-binding domain, interacting with DNA via the minor groove.","method":"NMR structure determination (NOEs, J-couplings, dipolar couplings); SELEX/SAAB DNA-binding assay; NMR titrations with DNA","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution NMR structure with multiple orthogonal validation methods (dipolar couplings, SAAB, NMR titrations) in a single focused study","pmids":["16384999"],"is_preprint":false},{"year":2011,"finding":"Tandem affinity purification (SBP/Flag-TAP) coupled with LC-MS/MS identified 106 proteins forming complexes with HDGF, placing it in complexes involved in ribosome biogenesis, RNA processing, DNA damage repair, and transcriptional regulation. The HATH domain was found to be essential for both protein–protein and protein–RNA interactions; deletion of HATH abolished complex formation. RNA co-immunoprecipitation (SBP-RIP) also detected RNA in the HDGF complex.","method":"SBP/Flag tandem affinity purification coupled to LC-MS/MS; Co-IP; RT-PCR; RIP assay; domain-deletion analysis","journal":"Journal of proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass-spectrometry interactome with domain-deletion validation and RIP, single lab; pan-interactome study but includes specific domain-function mapping for HDGF","pmids":["21907836"],"is_preprint":false},{"year":2011,"finding":"p53 transcriptionally represses HDGF by altering HDAC-dependent chromatin remodeling. Wild-type p53 introduction decreased endogenous HDGF expression; conditioned medium from p53-expressing cells blocked cell growth, migration, and invasion, effects reversible by recombinant HDGF addition. Mechanistic studies showed p53 represses HDGF transcription through chromatin remodeling involving HDACs.","method":"p53 overexpression in cancer cells; HDGF neutralizing antibody; recombinant HDGF rescue; chromatin remodeling (HDAC-dependent) mechanistic analysis; Western blot; cell growth and migration assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (p53 introduction) plus pharmacological (HDAC), rescue with recombinant protein, single lab with multiple orthogonal approaches","pmids":["22006999"],"is_preprint":false},{"year":2011,"finding":"Cell surface heparan sulfates (HS) are required for HDGF internalization. Cells lacking surface HS could not internalize HDGF, its HATH domain, or a receptor-binding-deficient HATH mutant (K96A). Both HATH and HATH(K96A) enter cells via macropinocytosis after binding cell surface HS. HS-mediated internalization of HATH(K96A) inhibited cell migration and proliferation (opposite to HATH), and MAPK signaling pathways were differentially affected by the two constructs, regulating matrix metalloprotease expression in NIH 3T3 fibroblasts.","method":"HS-deficient cell lines; macropinocytosis inhibition assays; site-directed mutagenesis (K96A); cell migration/proliferation assays; MAPK pathway analysis; MMP expression analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis combined with HS-deficient cell lines, macropinocytosis assays, and functional readouts in a single focused study demonstrating mechanism","pmids":["20964630"],"is_preprint":false},{"year":2012,"finding":"HDGF forms heteromers with HRP-2 isoforms. A newly identified splice variant of HRP-2 (isoform c, with 53-amino acid deletion in the HATH region) preferentially interacts with a processed form of HDGF and, unlike other HRP-2 isoforms, binds to chromatin. HRP-2 isoform c and the processed form of HDGF are both displaced from condensed mitotic metaphase chromatin.","method":"Co-immunoprecipitation; chromatin fractionation; identification of splice variant by molecular cloning; mitotic chromatin displacement assay","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus chromatin fractionation, single lab, two orthogonal methods","pmids":["22212508"],"is_preprint":false},{"year":2008,"finding":"HDGF undergoes caspase-dependent dephosphorylation during the early steps of TNF+cycloheximide-induced apoptosis in endothelial cells, prior to mitochondrial membrane permeabilization. This event was blocked by the pan-caspase inhibitor zVADfmk, placing HDGF dephosphorylation downstream of an initiator caspase. Nuclear localization of GFP-HDGF was unaffected by the apoptotic stimulus.","method":"2D gel electrophoresis of 32P-labeled samples; mass spectrometry identification; Western blot; zVADfmk caspase inhibition; GFP-HDGF live-cell imaging","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomic identification plus pharmacological (caspase inhibitor) epistasis, GFP imaging, single lab","pmids":["18465786"],"is_preprint":false},{"year":2014,"finding":"NMR H2CN titration experiments identified lysine K19 as the key residue in HDGF mediating electrostatic interaction with heparin, with side-chain chemical shift perturbations correlating with binding free energy changes in site-directed mutants. Backbone chemical shifts did not reliably report on heparin binding at this buried residue.","method":"H2CN NMR pulse sequence; heparin titration; site-directed mutagenesis; free energy correlation analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro NMR with mutagenesis and free energy correlation, single lab with multiple orthogonal NMR methods","pmids":["25117899"],"is_preprint":false},{"year":2017,"finding":"HDGF forms a complex with DDX5 and β-catenin. Co-immunoprecipitation combined with mass spectrometry and GST pull-down demonstrated that DDX5 directly interacts with HDGF, and HDGF/DDX5 induces β-catenin–c-Myc signaling, which suppresses miR-296-3p expression in lung adenocarcinoma cells. ChIP and EMSA assays further characterized the DNA-protein interactions in this pathway.","method":"Co-immunoprecipitation combined with mass spectrometry; GST pull-down; ChIP; EMSA; Western blot; luciferase reporter assay","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus MS and GST pull-down for direct interaction, ChIP/EMSA for functional context, single lab","pmids":["28751441"],"is_preprint":false},{"year":2019,"finding":"ZEB1 transcription factor binds to the HDGF promoter to stimulate HDGF transcription, and ZEB1 also physically interacts with HDGF protein and co-localizes with it in the nucleus. HDGF in turn activates β-catenin/TCF4 signaling, which feeds back to stimulate ZEB1 transcription, creating a ZEB1/HDGF/β-catenin/TCF4 positive feedback loop promoting endometrial cancer metastasis.","method":"ChIP assay (ZEB1 promoter binding); co-immunoprecipitation (ZEB1–HDGF interaction); immunofluorescence co-localization; siRNA knockdown; β-catenin nuclear translocation assay; in vitro and in vivo functional assays","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus nuclear translocation assays, single lab, multiple orthogonal methods","pmids":["31815037"],"is_preprint":false},{"year":2020,"finding":"HDGF drives Ewing sarcoma (ES) metastasis by functioning as a transcription factor. ChIP-seq and gene expression profiling revealed that HDGF directly regulates the ALCAM gene, repressing its expression. HDGF downregulation of ALCAM induces expression and activation of Rho-GTPases Rac1 and Cdc42, promoting actin cytoskeleton remodeling and cell-matrix adhesion to enhance metastasis. Repression of ALCAM and activation of Rac1/Cdc42 are required for HDGF's pro-metastatic functions.","method":"HDGF ChIP-seq; gene expression profiling; siRNA/shRNA knockdown; Rac1/Cdc42 activation assays; actin cytoskeleton imaging; orthotopic mouse model; experimental metastasis model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq plus expression profiling plus functional in vitro and in vivo validation with multiple mechanistic readouts, single lab but comprehensive","pmids":["33239755"],"is_preprint":false},{"year":2021,"finding":"NAP1L1 interacts with HDGF at the protein level and co-localizes with it in the cytoplasm. HDGF in turn interacts with the transcription factor c-Jun, which induces expression of cell-cycle promoters CCND1/CDK4/CDK6. HDGF knockdown in NAP1L1-overexpressing glioma cells inhibits proliferation, establishing a NAP1L1→HDGF→c-Jun→CCND1/CDK4/CDK6 signaling axis.","method":"Co-immunoprecipitation; immunofluorescence co-localization; siRNA knockdown; Western blot; in vitro and in vivo proliferation assays","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus immunofluorescence co-localization plus rescue experiments, single lab","pmids":["34959221"],"is_preprint":false},{"year":2022,"finding":"NAP1L1 interacts with HDGF and co-localizes in the cytoplasm of ovarian cancer cells. HDGF interacts with c-Jun (C-JUN), which then induces CCND1 expression to promote cell proliferation. HDGF overexpression in NAP1L1-knockdown OC cells restores C-JUN and CCND1 expression and reverses the anti-proliferative effects, confirming HDGF acts downstream of NAP1L1 through HDGF/C-JUN signaling.","method":"Co-immunoprecipitation; immunofluorescence; siRNA and shRNA knockdown; Western blot; CCK-8; EDU assay; flow cytometry; colony formation assay","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus co-localization plus rescue experiments, single lab, replicates findings from PMID:34959221 in a different cancer type","pmids":["35351053"],"is_preprint":false},{"year":2022,"finding":"G3BP2 binds to HDGF mRNA transcripts to stabilize HDGF expression. RNA-seq in ESCC cells revealed HDGF as regulated by G3BP2, and G3BP2 depletion reduced HDGF protein levels. Ectopic HDGF expression rescued G3BP2-depletion-mediated inhibition of ESCC cell migration, placing G3BP2-mediated HDGF mRNA stabilization in the LINC01554/G3BP2/HDGF regulatory axis.","method":"RNA-seq; Western blot; qRT-PCR; rescue overexpression experiments; in vitro migration assays; in vivo xenograft","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq plus rescue experiments identifying post-transcriptional regulation mechanism, single lab","pmids":["34782720"],"is_preprint":false},{"year":2022,"finding":"METTL3-mediated N6-methyladenosine (m6A) RNA methylation of HDGF mRNA enhances its mRNA stability and protein expression in M1 macrophages during atherosclerosis. Elevated METTL3 in M1 macrophages increases HDGF protein via m6A modification; HDGF in turn regulates M1 macrophage polarization through energy metabolism reprogramming (glycolysis, mitochondrial function), contributing to atherosclerotic plaque formation.","method":"m6A RNA methylation analysis; macrophage-specific HDGF knockout mouse (ApoeKO model); Western blot; metabolic assays (glycolysis, mitochondria); in vivo plaque quantification","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A modification with in vivo KO model and metabolic readouts, single lab","pmids":["36265285"],"is_preprint":false},{"year":2023,"finding":"HDGF stimulates mitochondrial reactive oxygen species (ROS) generation and upregulates oxidative phosphorylation and bioenergetics in hepatoma cells (increased basal and total oxygen consumption rate, extracellular acidification rate). This is mediated through the HDGF receptor nucleolin (NCL) on the cell surface: genetic knockdown of NCL and anti-NCL antibody abolished HDGF-induced ROS and mitochondrial energetic increases. An inactive Ser103Ala mutant of recombinant HDGF failed to promote ROS generation or oncogenic behaviors.","method":"Recombinant HDGF treatment; Ser103Ala mutagenesis; Seahorse metabolic flux assay; ROS-detecting fluorescent dyes; flow cytometry; NCL knockdown (siRNA); anti-NCL antibody neutralization; MitoQ/NAC antioxidant treatment; SOD2 knockdown; in vivo orthotopic hepatoma model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant protein, active-site mutagenesis (Ser103Ala), receptor identification with antibody neutralization and siRNA, Seahorse metabolic profiling; multiple orthogonal methods in single study","pmids":["37827291"],"is_preprint":false},{"year":2023,"finding":"HDGF promotes gefitinib resistance in NSCLC by activating the PI3K/AKT and MEK/ERK signaling pathways independently of EGFR phosphorylation. Gefitinib treatment induced HDGF expression; effects of HDGF on gefitinib resistance were largely attenuated by the AKT inhibitor MK2206 or the ERK inhibitor U0126, establishing epistatic placement of HDGF upstream of these pathways.","method":"Stable HDGF KO and overexpression cell lines; AKT inhibitor (MK2206); ERK inhibitor (U0126); ELISA; Western blot; in vitro and in vivo drug resistance assays","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO/OE with pharmacological epistasis (two independent pathway inhibitors), single lab","pmids":["37301856"],"is_preprint":false},{"year":2025,"finding":"HDGF modulates DNA damage response by recruiting CtIP (C-terminal binding protein-interacting protein) to facilitate homologous recombination (HR) repair, thereby influencing drug sensitivity in colorectal cancer. HDGF is proposed to function as a recognition protein for H3K36me3, participating in the repair of transcriptionally active damaged genes to maintain genomic stability.","method":"HDGF knockout cells; CtIP interaction/recruitment assays; HR repair assays; drug sensitivity assays; Western blot","journal":"Biomolecules","confidence":"Low","confidence_rationale":"Tier 3 / Weak — CtIP recruitment and HR assays described but limited methodological detail in abstract; single lab, single study","pmids":["40001585"],"is_preprint":false},{"year":2024,"finding":"The m6A reader IGF2BP2 binds to and stabilizes HDGF mRNA transcripts in an m6A-dependent manner in esophageal squamous cell carcinoma (ESCC), promoting HDGF protein expression and ESCC proliferation, migration, invasion, and tumorigenicity.","method":"m6A-dependent RNA binding assays (IGF2BP2–HDGF mRNA); siRNA/overexpression; in vitro proliferation/migration/invasion assays; in vivo tumorigenicity","journal":"Journal of cancer research and therapeutics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — binding interaction described but limited mechanistic detail in abstract; single lab","pmids":["39206979"],"is_preprint":false},{"year":2016,"finding":"In ovarian cancer cells, HDGF localizes predominantly in the nucleus but is minimally secreted under normal conditions. However, HDGF is passively released by necrotic and late apoptotic cells. Extracellular HDGF stimulates phosphorylation of ERK1/2 and p38 MAPK and enhances cellular migration in both cancer and non-cancer cells, suggesting HDGF functions as an alarmin.","method":"Immunofluorescence (nuclear localization); conditioned media analysis; necrosis/apoptosis induction assays; ERK1/2 and p38 phosphorylation assays (Western blot); cell migration assays","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by immunofluorescence with functional consequence (ERK/p38 signaling, migration), single lab, two orthogonal methods","pmids":["26612514"],"is_preprint":false},{"year":2004,"finding":"Subcellular localization of HDGF was determined experimentally in cultured neocortical neurons: HDGF is restricted to the neuronal soma and is present in both nucleus and cytoplasm, while the related HRP-3 can additionally be found in neurites. Simultaneous expression in the same cell with different subcellular distributions suggests different intracellular functions for HDGF and HRP-3.","method":"Immunocytochemistry; in situ hybridization; immunohistochemistry; generation of isoform-specific antisera","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct immunocytochemistry-based localization with isoform-specific antisera in primary cultures, single lab","pmids":["14572309"],"is_preprint":false},{"year":2012,"finding":"HDGF secreted by glioblastoma stem-like cells (GSCs) functions as a pro-angiogenic factor. Anti-HDGF antibodies blocked GSC-conditioned medium-induced migration of cerebral endothelial cells. In vivo, GSC-conditioned medium induced neoangiogenesis, and HDGF-targeting siRNAs abrogated this effect.","method":"Proteomic 2D-DIGE and MS identification; anti-HDGF antibody neutralization; endothelial cell migration assay; in vivo Matrigel neoangiogenesis model; HDGF siRNA knockdown","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization plus siRNA with in vivo angiogenesis assay, single lab, two orthogonal methods","pmids":["22331796"],"is_preprint":false},{"year":2015,"finding":"Hepatocellular carcinoma cell-derived HDGF induces generation of Foxp3+ regulatory T cells (Tregs) from CD4+CD25- T cells. Exposure to recombinant HDGF increased Foxp3 expression and decreased GATA3 expression in CD4+ T cells. The induced Tregs suppressed CD8+ T cell proliferation and cytotoxic cytokine release, linking HDGF to immune evasion.","method":"HDGF expression by qRT-PCR and Western blot; co-culture of hepatoma cells with CD4+CD25- T cells; flow cytometry for Foxp3; CFSE-dilution assay for CD8+ suppression; ELISA for cytokines","journal":"Cytokine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — recombinant protein treatment with functional T cell assays, flow cytometry, CFSE suppression assay; single lab","pmids":["25569374"],"is_preprint":false},{"year":2020,"finding":"HDGF functions as an angiogenic factor that enhances VEGF-dependent angiogenesis in EBC-1 NSCLC cells (but not in Lu99 cells). Tube formation, neutralization, and RNA interference assays using both standard and novel 3D collagen-gel culture supernatants demonstrated that HDGF and VEGF-A cooperate in angiogenesis in a cell-line-dependent manner.","method":"Mass spectrometry protein identification from serum-free conditioned medium; endothelial tube formation assay; neutralizing antibody; siRNA knockdown; 3D collagen gel culture; gene microarray","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization plus siRNA in two independent culture systems (standard and 3D), single lab","pmids":["32319650"],"is_preprint":false},{"year":2022,"finding":"HDGF is present inside extracellular vesicles (EVs) released by multiple myeloma cells and activates AKT phosphorylation in myeloma cells when added exogenously. HDGF also enhances glycolysis and reduces mitochondrial respiration in myeloma cells, and polarizes macrophages toward an M1-like phenotype while altering monocytes to resemble myeloid-derived suppressor cells.","method":"EV proteomic analysis; HDGF knockdown (proliferation assay); exogenous HDGF addition (AKT phosphorylation); Seahorse metabolic analysis; macrophage polarization assays; flow cytometry","journal":"Blood advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EV proteomics plus functional assays (AKT, Seahorse, macrophage polarization), single lab, multiple readouts","pmids":["35395072"],"is_preprint":false},{"year":2021,"finding":"HDGF activates KRAS transcription and suppresses RhoA transcription in prostate cancer cells; these transcriptional effects are mediated in part through HDGF's direct interaction with the helicase BLM. BLM co-immunoprecipitates with HDGF, and BLM depletion modulates HDGF-dependent effects on KRAS and RhoA, consequently activating the MAPK/ERK pathway.","method":"Co-immunoprecipitation (BLM–HDGF); ChIP-seq; dual-luciferase reporter assay; Western blot; in vitro functional assays (proliferation, migration, invasion); in vivo xenograft","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP-seq plus luciferase reporter, single lab","pmids":["36574142"],"is_preprint":false},{"year":2025,"finding":"FBXW7 E3 ubiquitin ligase directly interacts with and ubiquitinates NAP1L1, targeting it for proteasomal degradation. Reduced NAP1L1 impairs recruitment of the deubiquitinase USP14, limiting deubiquitination of HDGF and thus decreasing HDGF protein levels. In turn, reduced HDGF suppresses USP14-mediated deubiquitination of p62, decreasing p62 levels, and this HDGF/p62 signaling reduction triggers autophagy and enhances cisplatin sensitivity in NPC.","method":"Co-immunoprecipitation; ubiquitination assays; USP14 deubiquitination assay; Western blot; autophagosome formation assays; in vitro and in vivo NPC models; shRNA knockdown","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination/deubiquitination assays with functional in vivo NPC model, single lab, multiple orthogonal methods","pmids":["40414865"],"is_preprint":false},{"year":2019,"finding":"HDGF overexpression in NSCLC cells upregulates IL-4 expression in a dose-dependent manner. Secreted HDGF induces macrophage polarization toward the M2 phenotype through the IL-4/JAK1/STAT3 signaling pathway, thereby creating a pro-tumorigenic paracrine loop between NSCLC cells and tumor-associated macrophages.","method":"HDGF overexpression constructs; RNA-seq in HDGF-overexpressing cells; IL-4 ELISA; Western blot for JAK1/STAT3; flow cytometry for macrophage markers; co-culture assays; in vivo C57BL/6 tumor model with MTE treatment","journal":"Journal of ethnopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq plus ELISA plus Western blot with in vivo validation, single lab","pmids":["35973634"],"is_preprint":false},{"year":2025,"finding":"HDGF activates the SIRT1/PGC-1α/Nrf2 pathway and the p38 MAPK/AKT axis in retinal pigment epithelial cells, protecting against glyoxal-induced ferroptosis by restoring mitochondrial biogenesis (MFN2, PGC-1α, SIRT1), enhancing the glutathione/GPX4 antioxidant system, and suppressing lipid peroxidation.","method":"Recombinant HDGF treatment; Western blot for pathway components; ROS/lipid peroxidation assays; glutathione measurement; mitochondrial morphology assessment","journal":"Antioxidants","confidence":"Low","confidence_rationale":"Tier 3 / Weak — recombinant protein treatment with pathway readouts, single study, limited mechanistic depth in abstract","pmids":["41462634"],"is_preprint":false}],"current_model":"HDGF is a multifunctional heparin-binding nuclear protein whose N-terminal PWWP/HATH domain mediates nonspecific DNA binding and is required for protein–protein and protein–RNA interactions; it is internalized via heparan sulfate-dependent macropinocytosis, undergoes caspase-dependent dephosphorylation during apoptosis and Mettl3/m6A-dependent mRNA stabilization, acts as a transcription factor (e.g., repressing ALCAM in Ewing sarcoma downstream of its direct binding to target chromatin) and a signaling ligand that, upon binding its cell-surface receptor nucleolin, stimulates mitochondrial ROS generation and activates PI3K/AKT and MAPK/ERK pathways; its expression is negatively regulated by p53 through HDAC-dependent chromatin remodeling, and it participates in complexes with DDX5/β-catenin, NAP1L1, ZEB1, BLM, and HRP-2 isoforms to regulate cell cycle progression, EMT, angiogenesis, immune modulation, and drug resistance across multiple cancer contexts."},"narrative":{"mechanistic_narrative":"HDGF is a heparin-binding nuclear protein that functions both as a chromatin-associated transcriptional regulator and as a secreted signaling ligand, contributing to proliferation, metastasis, angiogenesis, immune modulation, and drug resistance across multiple cancers [PMID:33239755, PMID:37827291]. Its N-terminal PWWP/HATH domain is a high-resolution-defined fold that binds DNA nonspecifically through the minor groove and is essential for HDGF's protein-protein and protein-RNA interactions, with surface lysine residues (K19) mediating electrostatic engagement of heparin [PMID:16384999, PMID:21907836, PMID:25117899]. Cell-surface heparan sulfate is required for HDGF uptake, and HDGF and its HATH domain are internalized via macropinocytosis, with differential effects on migration, proliferation, and MAPK signaling depending on receptor-binding competence [PMID:20964630]. As a transcription factor, HDGF binds target chromatin directly to repress ALCAM in Ewing sarcoma, thereby activating Rac1/Cdc42 to drive cytoskeletal remodeling and metastasis, and it also transcriptionally regulates KRAS and RhoA through its interaction with the BLM helicase [PMID:33239755, PMID:36574142]. As an extracellular ligand released by necrotic and late apoptotic cells, HDGF stimulates ERK1/2 and p38 MAPK and acts through its cell-surface receptor nucleolin to drive mitochondrial ROS generation and bioenergetic reprogramming, an activity abolished by the Ser103Ala mutation [PMID:26612514, PMID:37827291]. HDGF participates in numerous oncogenic protein complexes—with DDX5/β-catenin, ZEB1, NAP1L1/c-Jun, and HRP-2 isoforms—coupling it to β-catenin, cell-cycle, and EMT programs [PMID:28751441, PMID:31815037, PMID:34959221, PMID:22212508]. HDGF expression is controlled at multiple levels: p53 represses it via HDAC-dependent chromatin remodeling, m6A readers and RNA-binding proteins (METTL3, IGF2BP2, G3BP2) stabilize its mRNA, and a USP14-dependent deubiquitination cascade controls its protein stability [PMID:22006999, PMID:36265285, PMID:34782720, PMID:40414865]. It further shapes the tumor microenvironment by promoting Treg induction, M2 macrophage polarization, and VEGF-dependent angiogenesis [PMID:25569374, PMID:35973634, PMID:32319650].","teleology":[{"year":2005,"claim":"The structural basis for HDGF's DNA association was unknown; defining the PWWP/HATH fold established it as a nonspecific minor-groove DNA-binding module.","evidence":"High-resolution NMR structure with SELEX/SAAB DNA-binding assays and NMR titrations","pmids":["16384999"],"confidence":"High","gaps":["No sequence-specific DNA recognition demonstrated","Does not address how nonspecific DNA binding relates to gene-specific transcriptional regulation"]},{"year":2011,"claim":"Whether HDGF acts within larger macromolecular assemblies was unclear; interactome mapping placed it in ribosome biogenesis, RNA processing, DNA repair, and transcription complexes and showed the HATH domain is essential for both protein and RNA interactions.","evidence":"Tandem affinity purification with LC-MS/MS, Co-IP, RIP, and domain-deletion analysis","pmids":["21907836"],"confidence":"Medium","gaps":["Direct vs. indirect interactions not resolved for most of the 106 proteins","Functional consequence of each complex not tested"]},{"year":2011,"claim":"The upstream regulation of HDGF was uncharacterized; p53 was shown to repress HDGF transcription via HDAC-dependent chromatin remodeling, linking HDGF to tumor suppressor control.","evidence":"p53 overexpression, HDAC mechanistic analysis, recombinant HDGF rescue of conditioned-medium effects","pmids":["22006999"],"confidence":"Medium","gaps":["Direct p53 binding to the HDGF promoter not shown","Specific HDAC enzymes not identified"]},{"year":2010,"claim":"How extracellular HDGF enters cells was unknown; heparan sulfate-dependent macropinocytosis was established as the uptake route, with receptor-binding competence dictating opposing effects on cell behavior.","evidence":"HS-deficient cell lines, K96A mutagenesis, macropinocytosis inhibition, MAPK and MMP readouts in fibroblasts","pmids":["20964630"],"confidence":"High","gaps":["The signaling receptor distinct from HS not identified in this study","Intracellular fate after internalization unresolved"]},{"year":2008,"claim":"Whether HDGF is post-translationally modified during cell death was unknown; caspase-dependent dephosphorylation was placed early in apoptosis, before mitochondrial permeabilization.","evidence":"32P-labeling 2D gels, MS, zVADfmk caspase inhibition, GFP-HDGF imaging in endothelial cells","pmids":["18465786"],"confidence":"Medium","gaps":["The phosphatase responsible not identified","Functional consequence of dephosphorylation not established"]},{"year":2012,"claim":"The relationship between HDGF and its HRP-2 paralog isoforms was unclear; a HATH-truncated HRP-2 splice variant was shown to preferentially bind a processed HDGF form and associate with chromatin, both displaced from mitotic chromatin.","evidence":"Reciprocal Co-IP, chromatin fractionation, molecular cloning, mitotic displacement assay","pmids":["22212508"],"confidence":"Medium","gaps":["Nature of the processed HDGF form not defined","Functional role of cell-cycle chromatin displacement unknown"]},{"year":2014,"claim":"The molecular determinant of HDGF's heparin binding was uncharacterized; K19 was identified as the key electrostatic contact residue using side-chain-specific NMR.","evidence":"H2CN NMR pulse sequence, heparin titration, mutagenesis, binding free-energy correlation","pmids":["25117899"],"confidence":"High","gaps":["In vivo relevance of K19 to HS-dependent uptake not tested","Whether heparin binding modulates signaling not addressed"]},{"year":2012,"claim":"It was unknown whether secreted HDGF drives tumor vascularization; glioblastoma stem-cell-derived HDGF was shown to act as a pro-angiogenic factor.","evidence":"2D-DIGE/MS identification, anti-HDGF neutralization, endothelial migration, in vivo Matrigel neoangiogenesis, siRNA","pmids":["22331796"],"confidence":"Medium","gaps":["Receptor on endothelial cells not identified","Relationship to VEGF not addressed in this study"]},{"year":2015,"claim":"The immunomodulatory role of HDGF was undefined; hepatoma-derived HDGF was shown to induce Foxp3+ Tregs that suppress CD8+ T cells, implicating it in immune evasion.","evidence":"Recombinant HDGF treatment, Foxp3 flow cytometry, CFSE suppression assay, cytokine ELISA","pmids":["25569374"],"confidence":"Medium","gaps":["Receptor/signaling pathway in T cells not identified","In vivo relevance not tested"]},{"year":2016,"claim":"How HDGF reaches the extracellular space was unclear; it was shown to be predominantly nuclear and passively released by necrotic/late apoptotic cells, acting as an alarmin via ERK1/2 and p38.","evidence":"Immunofluorescence, conditioned media, necrosis/apoptosis induction, MAPK phosphorylation, migration assays","pmids":["26612514"],"confidence":"Medium","gaps":["No active secretion mechanism defined","Receptor mediating ERK/p38 activation not identified here"]},{"year":2017,"claim":"HDGF's coupling to Wnt signaling was unknown; a direct DDX5-HDGF complex was shown to drive β-catenin/c-Myc signaling and suppress miR-296-3p in lung adenocarcinoma.","evidence":"Co-IP/MS, GST pull-down, ChIP, EMSA, luciferase reporter","pmids":["28751441"],"confidence":"Medium","gaps":["Stoichiometry and direct DNA-binding role of HDGF in this complex unclear","Single cancer context"]},{"year":2019,"claim":"The interplay between HDGF and EMT regulators was undefined; a ZEB1/HDGF/β-catenin/TCF4 positive feedback loop was established in endometrial cancer.","evidence":"ChIP, Co-IP, immunofluorescence co-localization, siRNA, in vivo assays","pmids":["31815037"],"confidence":"Medium","gaps":["Direct vs. cofactor role of HDGF at ZEB1-regulated promoters not resolved","Single cancer type"]},{"year":2019,"claim":"HDGF's effect on tumor macrophages was unknown; secreted HDGF was shown to drive M2 polarization via the IL-4/JAK1/STAT3 axis in NSCLC.","evidence":"Overexpression, RNA-seq, IL-4 ELISA, JAK1/STAT3 Western blot, co-culture, in vivo model","pmids":["35973634"],"confidence":"Medium","gaps":["Direct receptor for HDGF on macrophages not identified","Mechanism of IL-4 induction by HDGF unclear"]},{"year":2020,"claim":"Whether HDGF directly programs metastatic gene expression was open; ChIP-seq showed HDGF directly represses ALCAM, activating Rac1/Cdc42 to drive Ewing sarcoma metastasis.","evidence":"HDGF ChIP-seq, expression profiling, knockdown, Rac1/Cdc42 activation assays, orthotopic and metastasis mouse models","pmids":["33239755"],"confidence":"High","gaps":["Genome-wide direct target set beyond ALCAM not fully resolved","Cofactors at the ALCAM locus not defined"]},{"year":2020,"claim":"The relationship between HDGF and canonical angiogenic factors was unclear; HDGF was shown to cooperate with VEGF-A in a cell-line-dependent manner to enhance angiogenesis.","evidence":"MS identification, tube formation, neutralizing antibody, siRNA, 3D collagen-gel culture, microarray","pmids":["32319650"],"confidence":"Medium","gaps":["Basis for cell-line dependence unexplained","Molecular link between HDGF and VEGF not defined"]},{"year":2021,"claim":"How HDGF cooperates with chromatin factors to control oncogenes was unknown; a direct HDGF-BLM interaction was shown to activate KRAS and repress RhoA transcription, feeding MAPK/ERK signaling in prostate cancer.","evidence":"Co-IP, ChIP-seq, dual-luciferase reporter, in vitro and in vivo assays","pmids":["36574142"],"confidence":"Medium","gaps":["Direct DNA binding of HDGF at KRAS/RhoA loci not separated from BLM contribution","Helicase-dependence not tested"]},{"year":2021,"claim":"An upstream activator of HDGF in proliferation was unknown; NAP1L1 was shown to interact with HDGF, channeling into an HDGF→c-Jun→CCND1/CDK4/CDK6 cell-cycle axis in glioma.","evidence":"Co-IP, immunofluorescence co-localization, siRNA, proliferation assays in vitro and in vivo","pmids":["34959221"],"confidence":"Medium","gaps":["Direct vs. indirect NAP1L1-HDGF binding not resolved","How HDGF activates c-Jun not defined"]},{"year":2022,"claim":"Generality of the NAP1L1/HDGF/c-Jun axis was uncertain; the same axis was confirmed in ovarian cancer with HDGF acting downstream of NAP1L1 to restore C-JUN and CCND1.","evidence":"Co-IP, immunofluorescence, knockdown/rescue, proliferation and cell-cycle assays","pmids":["35351053"],"confidence":"Medium","gaps":["Mechanism unchanged from prior study; direct interaction nature still unresolved"]},{"year":2022,"claim":"Post-transcriptional control of HDGF was undefined; G3BP2 was shown to bind and stabilize HDGF mRNA within a LINC01554/G3BP2/HDGF axis driving ESCC migration.","evidence":"RNA-seq, qRT-PCR, Western blot, rescue overexpression, migration and xenograft assays","pmids":["34782720"],"confidence":"Medium","gaps":["Direct G3BP2-HDGF mRNA binding sites not mapped","Relation to m6A regulation not addressed here"]},{"year":2022,"claim":"Whether m6A modification controls HDGF was unknown; METTL3-mediated m6A was shown to stabilize HDGF mRNA in M1 macrophages, with HDGF reprogramming energy metabolism in atherosclerosis.","evidence":"m6A analysis, macrophage-specific HDGF KO ApoeKO mice, metabolic assays, plaque quantification","pmids":["36265285"],"confidence":"Medium","gaps":["m6A reader linking METTL3 to HDGF stability not identified here","Direct metabolic targets of HDGF unclear"]},{"year":2022,"claim":"Whether HDGF travels in vesicles and signals metabolically was open; HDGF was found in myeloma extracellular vesicles and shown to activate AKT, shift glycolysis, and polarize immune cells.","evidence":"EV proteomics, exogenous HDGF treatment, AKT phosphorylation, Seahorse, macrophage/monocyte assays","pmids":["35395072"],"confidence":"Medium","gaps":["Receptor mediating EV-HDGF AKT activation not identified","Mechanism of metabolic shift unresolved"]},{"year":2023,"claim":"The cell-surface receptor for HDGF signaling and its bioenergetic mechanism were unknown; nucleolin was identified as the HDGF receptor mediating mitochondrial ROS and OXPHOS upregulation, with Ser103 required for activity.","evidence":"Recombinant HDGF, Ser103Ala mutant, Seahorse, ROS assays, NCL knockdown and antibody neutralization, antioxidant treatment, orthotopic hepatoma model","pmids":["37827291"],"confidence":"High","gaps":["How nucleolin transduces signal to mitochondria not defined","Role of Ser103 phosphorylation status not established"]},{"year":2023,"claim":"HDGF's contribution to targeted-therapy resistance was unclear; it was shown to confer gefitinib resistance in NSCLC by activating PI3K/AKT and MEK/ERK independently of EGFR.","evidence":"Stable KO/OE lines, MK2206 and U0126 pathway inhibitors, ELISA, in vitro and in vivo drug-resistance assays","pmids":["37301856"],"confidence":"Medium","gaps":["Mechanism by which HDGF activates these kinases not defined","Link to nucleolin signaling not tested"]},{"year":2024,"claim":"Whether an m6A reader stabilizes HDGF mRNA was open; IGF2BP2 was shown to bind and stabilize HDGF mRNA in an m6A-dependent manner in ESCC.","evidence":"m6A-dependent RNA binding assays, knockdown/overexpression, proliferation/migration/invasion and tumorigenicity assays","pmids":["39206979"],"confidence":"Low","gaps":["Limited mechanistic detail in abstract; m6A sites not mapped","Relationship to METTL3/G3BP2 regulation unresolved"]},{"year":2025,"claim":"A proteostatic mechanism controlling HDGF was unknown; an FBXW7→NAP1L1→USP14 cascade was shown to govern HDGF deubiquitination, with HDGF/p62 signaling regulating autophagy and cisplatin sensitivity in NPC.","evidence":"Co-IP, ubiquitination/deubiquitination assays, autophagosome assays, in vitro and in vivo NPC models, shRNA","pmids":["40414865"],"confidence":"Medium","gaps":["Direct USP14-HDGF deubiquitination not fully isolated from NAP1L1 dependence","Ubiquitin chain type on HDGF not defined"]},{"year":2025,"claim":"A potential role for HDGF in chromatin-coupled DNA repair was proposed; HDGF was suggested to read H3K36me3 and recruit CtIP to facilitate homologous recombination in colorectal cancer.","evidence":"HDGF KO cells, CtIP recruitment and HR repair assays, drug-sensitivity assays","pmids":["40001585"],"confidence":"Low","gaps":["H3K36me3 recognition not directly demonstrated","Direct HDGF-CtIP interaction not confirmed with limited detail","Mechanism of HR facilitation unclear"]},{"year":2025,"claim":"A cytoprotective role for HDGF outside cancer was proposed; recombinant HDGF was shown to protect retinal pigment epithelium from ferroptosis via SIRT1/PGC-1α/Nrf2 and p38 MAPK/AKT.","evidence":"Recombinant HDGF treatment, pathway Western blots, ROS/lipid peroxidation and glutathione assays, mitochondrial morphology","pmids":["41462634"],"confidence":"Low","gaps":["Receptor and direct mechanism not defined","Single study with limited mechanistic depth"]},{"year":null,"claim":"How HDGF's nuclear chromatin-regulatory functions are mechanistically linked to its extracellular nucleolin-mediated signaling, and whether a single histone-mark reader activity unifies its transcription and DNA-repair roles, remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of the secreted ligand-nucleolin complex","Histone-mark reading by the PWWP domain not directly demonstrated in human HDGF","Whether nuclear and extracellular pools represent distinct functional states is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[9,24]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[14,18]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[3,6]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[18,19,4]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,11,19]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[18,20,22]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,14]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[9,24]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[21,26]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[12,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,15,25]}],"complexes":["HDGF-DDX5-β-catenin complex","HDGF-HRP-2 heteromer"],"partners":["NCL","DDX5","ZEB1","NAP1L1","BLM","CTIP","HRP-2","CTNNB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51858","full_name":"Hepatoma-derived growth factor","aliases":["High mobility group protein 1-like 2","HMG-1L2"],"length_aa":240,"mass_kda":26.8,"function":"Acts as a transcriptional repressor (PubMed:17974029). Has mitogenic activity for fibroblasts (PubMed:11751870, PubMed:26845719). Heparin-binding protein (PubMed:15491618) Does not have mitogenic activity for fibroblasts (PubMed:26845719). Does not bind heparin (PubMed:26845719) Has mitogenic activity for fibroblasts (PubMed:26845719). Heparin-binding protein (PubMed:26845719)","subcellular_location":"Nucleus; Cytoplasm; Secreted, extracellular exosome","url":"https://www.uniprot.org/uniprotkb/P51858/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HDGF","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CAPZB","stoichiometry":0.2},{"gene":"SLC7A6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HDGF","total_profiled":1310},"omim":[{"mim_id":"617884","title":"HEPATOMA-DERIVED GROWTH FACTOR-LIKE PROTEIN 2; HDGFL2","url":"https://www.omim.org/entry/617884"},{"mim_id":"616643","title":"HEPATOMA-DERIVED GROWTH FACTOR-RELATED PROTEIN 3","url":"https://www.omim.org/entry/616643"},{"mim_id":"600339","title":"HEPATOMA-DERIVED GROWTH FACTOR; HDGF","url":"https://www.omim.org/entry/600339"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HDGF"},"hgnc":{"alias_symbol":["HMG1L2"],"prev_symbol":[]},"alphafold":{"accession":"P51858","domains":[{"cath_id":"2.30.30.140","chopping":"13-91","consensus_level":"high","plddt":91.7146,"start":13,"end":91}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51858","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51858-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51858-F1-predicted_aligned_error_v6.png","plddt_mean":66.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HDGF","jax_strain_url":"https://www.jax.org/strain/search?query=HDGF"},"sequence":{"accession":"P51858","fasta_url":"https://rest.uniprot.org/uniprotkb/P51858.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51858/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51858"}},"corpus_meta":[{"pmid":"23954293","id":"PMC_23954293","title":"Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells.","date":"2013","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/23954293","citation_count":86,"is_preprint":false},{"pmid":"28751441","id":"PMC_28751441","title":"miRomics and Proteomics Reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc Feedback Loop Modulated by HDGF/DDX5/β-catenin Complex in Lung Adenocarcinoma.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28751441","citation_count":86,"is_preprint":false},{"pmid":"23673296","id":"PMC_23673296","title":"Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23673296","citation_count":84,"is_preprint":false},{"pmid":"25236340","id":"PMC_25236340","title":"HDGF: a novel jack-of-all-trades in cancer.","date":"2014","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25236340","citation_count":75,"is_preprint":false},{"pmid":"22331796","id":"PMC_22331796","title":"Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor.","date":"2012","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/22331796","citation_count":70,"is_preprint":false},{"pmid":"31632071","id":"PMC_31632071","title":"Long Noncoding RNA HCP5 Regulates Pancreatic Cancer Gemcitabine (GEM) Resistance By Sponging Hsa-miR-214-3p To Target HDGF.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31632071","citation_count":57,"is_preprint":false},{"pmid":"30684575","id":"PMC_30684575","title":"Long non-coding RNA AGAP2-AS1 promotes the proliferation of glioma cells by sponging miR-15a/b-5p to upregulate the expression of HDGF and activating Wnt/β-catenin signaling pathway.","date":"2019","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30684575","citation_count":56,"is_preprint":false},{"pmid":"16384999","id":"PMC_16384999","title":"High resolution structure of the HDGF PWWP domain: a potential DNA binding domain.","date":"2005","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/16384999","citation_count":56,"is_preprint":false},{"pmid":"14572309","id":"PMC_14572309","title":"Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/14572309","citation_count":51,"is_preprint":false},{"pmid":"23695169","id":"PMC_23695169","title":"Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23695169","citation_count":51,"is_preprint":false},{"pmid":"24891187","id":"PMC_24891187","title":"MiR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24891187","citation_count":48,"is_preprint":false},{"pmid":"24276755","id":"PMC_24276755","title":"miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF.","date":"2013","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24276755","citation_count":45,"is_preprint":false},{"pmid":"32319650","id":"PMC_32319650","title":"HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32319650","citation_count":44,"is_preprint":false},{"pmid":"12397753","id":"PMC_12397753","title":"Antisense oligonucleotides of hepatoma-derived growth factor (HDGF) suppress the proliferation of hepatoma cells.","date":"2002","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/12397753","citation_count":42,"is_preprint":false},{"pmid":"23609195","id":"PMC_23609195","title":"Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion.","date":"2013","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23609195","citation_count":34,"is_preprint":false},{"pmid":"22490522","id":"PMC_22490522","title":"HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas.","date":"2012","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22490522","citation_count":33,"is_preprint":false},{"pmid":"28693232","id":"PMC_28693232","title":"MicroRNA-195 inhibits the behavior of cervical cancer tumors by directly targeting HDGF.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28693232","citation_count":33,"is_preprint":false},{"pmid":"31815037","id":"PMC_31815037","title":"ZEB1 promotes invasion and metastasis of endometrial cancer by interacting with HDGF and inducing its transcription.","date":"2019","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31815037","citation_count":32,"is_preprint":false},{"pmid":"26175166","id":"PMC_26175166","title":"Differential proteomic analysis reveals that EGCG inhibits HDGF and activates apoptosis to increase the sensitivity of non-small cells lung cancer to chemotherapy.","date":"2015","source":"Proteomics. Clinical applications","url":"https://pubmed.ncbi.nlm.nih.gov/26175166","citation_count":31,"is_preprint":false},{"pmid":"21907836","id":"PMC_21907836","title":"Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF).","date":"2011","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/21907836","citation_count":28,"is_preprint":false},{"pmid":"32774748","id":"PMC_32774748","title":"Circular RNA circMAGI3 accelerates the glycolysis of non-small cell lung cancer through miR-515-5p/HDGF.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32774748","citation_count":27,"is_preprint":false},{"pmid":"33290265","id":"PMC_33290265","title":"Hsa_circ_0079480 promotes tumor progression in acute myeloid leukemia via miR-654-3p/HDGF axis.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33290265","citation_count":27,"is_preprint":false},{"pmid":"26612514","id":"PMC_26612514","title":"Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells.","date":"2016","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/26612514","citation_count":26,"is_preprint":false},{"pmid":"22006999","id":"PMC_22006999","title":"p53 negatively regulates the hepatoma growth factor HDGF.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22006999","citation_count":26,"is_preprint":false},{"pmid":"34959221","id":"PMC_34959221","title":"NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34959221","citation_count":26,"is_preprint":false},{"pmid":"33239755","id":"PMC_33239755","title":"A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33239755","citation_count":26,"is_preprint":false},{"pmid":"34782720","id":"PMC_34782720","title":"G3BP2 regulated by the lncRNA LINC01554 facilitates esophageal squamous cell carcinoma metastasis through stabilizing HDGF transcript.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34782720","citation_count":25,"is_preprint":false},{"pmid":"32194674","id":"PMC_32194674","title":"MicroRNA-139-5p inhibits cell viability, migration and invasion and suppresses tumor growth by targeting HDGF in non-small cell lung cancer.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32194674","citation_count":25,"is_preprint":false},{"pmid":"20964630","id":"PMC_20964630","title":"Cell surface heparan sulfates mediate internalization of the PWWP/HATH domain of HDGF via macropinocytosis to fine-tune cell signalling processes involved in fibroblast cell migration.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20964630","citation_count":25,"is_preprint":false},{"pmid":"35351053","id":"PMC_35351053","title":"NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.","date":"2022","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35351053","citation_count":24,"is_preprint":false},{"pmid":"24986090","id":"PMC_24986090","title":"A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.","date":"2014","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24986090","citation_count":24,"is_preprint":false},{"pmid":"35973634","id":"PMC_35973634","title":"Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF.","date":"2022","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35973634","citation_count":24,"is_preprint":false},{"pmid":"36265285","id":"PMC_36265285","title":"RNA-m6A modification of HDGF mediated by Mettl3 aggravates the progression of atherosclerosis by regulating macrophages polarization via energy metabolism reprogramming.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36265285","citation_count":24,"is_preprint":false},{"pmid":"31692549","id":"PMC_31692549","title":"Downregulation of HDGF inhibits the tumorigenesis of bladder cancer cells by inactivating the PI3K-AKT signaling pathway.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31692549","citation_count":23,"is_preprint":false},{"pmid":"18570251","id":"PMC_18570251","title":"Hepatoma-derived growth factor (HDGF) is dispensable for normal mouse development.","date":"2008","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/18570251","citation_count":21,"is_preprint":false},{"pmid":"20043047","id":"PMC_20043047","title":"shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer.","date":"2010","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/20043047","citation_count":20,"is_preprint":false},{"pmid":"25689719","id":"PMC_25689719","title":"HDGF-related protein-2 (HRP-2) acts as an oncogene to promote cell growth in hepatocellular carcinoma.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25689719","citation_count":20,"is_preprint":false},{"pmid":"25677618","id":"PMC_25677618","title":"Irradiated fibroblasts promote epithelial-mesenchymal transition and HDGF expression of esophageal squamous cell carcinoma.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25677618","citation_count":20,"is_preprint":false},{"pmid":"33130420","id":"PMC_33130420","title":"Exosomal lncRNA HEIH promotes cisplatin resistance in tongue squamous cell carcinoma via targeting miR-3619-5p/HDGF axis.","date":"2020","source":"Acta histochemica","url":"https://pubmed.ncbi.nlm.nih.gov/33130420","citation_count":20,"is_preprint":false},{"pmid":"34376200","id":"PMC_34376200","title":"Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34376200","citation_count":20,"is_preprint":false},{"pmid":"31469292","id":"PMC_31469292","title":"Long noncoding RNA LINC00342 promotes growth of infantile hemangioma by sponging miR-3619-5p from HDGF.","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31469292","citation_count":19,"is_preprint":false},{"pmid":"37301856","id":"PMC_37301856","title":"HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37301856","citation_count":18,"is_preprint":false},{"pmid":"31726370","id":"PMC_31726370","title":"LncRNA TDRG1 promotes the aggressiveness of gastric carcinoma through regulating miR-873-5p/HDGF axis.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31726370","citation_count":18,"is_preprint":false},{"pmid":"26637859","id":"PMC_26637859","title":"Down-regulation of HDGF Inhibits the Growth of Hepatocellular Carcinoma Cells In Vitro and In Vivo.","date":"2015","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26637859","citation_count":18,"is_preprint":false},{"pmid":"33556623","id":"PMC_33556623","title":"Crystal structure of the BRPF2 PWWP domain in complex with DNA reveals a different binding mode than the HDGF family of PWWP domains.","date":"2021","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/33556623","citation_count":18,"is_preprint":false},{"pmid":"32418767","id":"PMC_32418767","title":"MicroRNA-95-3p inhibits cell proliferation and metastasis in colorectal carcinoma by HDGF.","date":"2020","source":"Biomedical journal","url":"https://pubmed.ncbi.nlm.nih.gov/32418767","citation_count":17,"is_preprint":false},{"pmid":"31257090","id":"PMC_31257090","title":"Upregulation of miR‑95-3p inhibits growth of osteosarcoma by targeting HDGF.","date":"2019","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/31257090","citation_count":15,"is_preprint":false},{"pmid":"25569374","id":"PMC_25569374","title":"Hepatocarcinoma cell-derived hepatoma-derived growth factor (HDGF) induces regulatory T cells.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/25569374","citation_count":14,"is_preprint":false},{"pmid":"36148951","id":"PMC_36148951","title":"NAP1L1 promotes the growth of colon cancer by activating HDGF/DDX5.","date":"2022","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/36148951","citation_count":13,"is_preprint":false},{"pmid":"33817254","id":"PMC_33817254","title":"Long non-coding RNA SNHG3 accelerates progression in glioma by modulating miR-384/HDGF axis.","date":"2020","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33817254","citation_count":13,"is_preprint":false},{"pmid":"33718512","id":"PMC_33718512","title":"miR-1254 induced by NESG1 inactivates HDGF/DDX5-stimulated nuclear translocation of β-catenin and suppresses NPC metastasis.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/33718512","citation_count":13,"is_preprint":false},{"pmid":"35388952","id":"PMC_35388952","title":"lncRNA DLG1-AS1 promotes cervical cancer cell gemcitabine resistance by regulating miR-16-5p/HDGF.","date":"2022","source":"The journal of obstetrics and gynaecology research","url":"https://pubmed.ncbi.nlm.nih.gov/35388952","citation_count":11,"is_preprint":false},{"pmid":"28713954","id":"PMC_28713954","title":"MicroRNA‑139 suppressed tumor cell proliferation, migration and invasion by directly targeting HDGF in epithelial ovarian cancer.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28713954","citation_count":11,"is_preprint":false},{"pmid":"32214826","id":"PMC_32214826","title":"Long Non-Coding RNA ASB16-AS1 Functions as a miR-760 Sponge to Facilitate the Malignant Phenotype of Osteosarcoma by Increasing HDGF Expression.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32214826","citation_count":11,"is_preprint":false},{"pmid":"31511210","id":"PMC_31511210","title":"[Curcumin suppresses invasiveness and migration of human glioma cells in vitro by inhibiting HDGF/β-catenin complex].","date":"2019","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/31511210","citation_count":11,"is_preprint":false},{"pmid":"26392778","id":"PMC_26392778","title":"The expression and clinical significance of HDGF in osteosarcoma.","date":"2015","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26392778","citation_count":10,"is_preprint":false},{"pmid":"34895232","id":"PMC_34895232","title":"CCNI2 promotes the progression of human gastric cancer through HDGF.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34895232","citation_count":10,"is_preprint":false},{"pmid":"32547060","id":"PMC_32547060","title":"MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32547060","citation_count":10,"is_preprint":false},{"pmid":"25117899","id":"PMC_25117899","title":"NMR characterization of the electrostatic interaction of the basic residues in HDGF and FGF2 during heparin binding.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25117899","citation_count":10,"is_preprint":false},{"pmid":"37827291","id":"PMC_37827291","title":"HDGF stimulates liver tumorigenesis by enhancing reactive oxygen species generation in mitochondria.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37827291","citation_count":9,"is_preprint":false},{"pmid":"36574142","id":"PMC_36574142","title":"BLM promotes malignancy in PCa by inducing KRAS expression and RhoA suppression via its interaction with HDGF and activation of MAPK/ERK pathway.","date":"2022","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/36574142","citation_count":9,"is_preprint":false},{"pmid":"22212508","id":"PMC_22212508","title":"Interaction of HRP-2 isoforms with HDGF: chromatin binding of a specific heteromer.","date":"2012","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/22212508","citation_count":9,"is_preprint":false},{"pmid":"35578240","id":"PMC_35578240","title":"MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF.","date":"2022","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/35578240","citation_count":9,"is_preprint":false},{"pmid":"18465786","id":"PMC_18465786","title":"HDGF is dephosphorylated during the early steps of endothelial cell apoptosis in a caspase-dependent way.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18465786","citation_count":8,"is_preprint":false},{"pmid":"15086185","id":"PMC_15086185","title":"Circulating auto-antibody against hepatoma-derived growth factor (HDGF) in patients with ulcerative colitis.","date":"2004","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15086185","citation_count":8,"is_preprint":false},{"pmid":"34978893","id":"PMC_34978893","title":"MiR-769-5p, Which Targets HDGF, Inhibits Cell Proliferation and Invasion in Nonsmall Cell Lung Cancer.","date":"2026","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/34978893","citation_count":7,"is_preprint":false},{"pmid":"34314948","id":"PMC_34314948","title":"miR-4323 targets hepatoma-derived growth factor (HDGF) to suppress colorectal cancer cell proliferation.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/34314948","citation_count":7,"is_preprint":false},{"pmid":"26081074","id":"PMC_26081074","title":"Downregulation of the expression of HDGF attenuates malignant biological behaviors of hilar cholangiocarcinoma cells.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26081074","citation_count":6,"is_preprint":false},{"pmid":"40001585","id":"PMC_40001585","title":"HDGF Knockout Suppresses Colorectal Cancer Progression and Drug Resistance by Modulating the DNA Damage Response.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40001585","citation_count":5,"is_preprint":false},{"pmid":"39206979","id":"PMC_39206979","title":"The m6A reader IGF2BP2 promotes ESCC progression by stabilizing HDGF mRNA.","date":"2024","source":"Journal of cancer research and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/39206979","citation_count":4,"is_preprint":false},{"pmid":"34348265","id":"PMC_34348265","title":"The Inhibitory Effect of miR-345 on Glioma Progression Is Closely Related to circRNA-hsa_circ_0073237 and HDGF.","date":"2021","source":"Cells, tissues, organs","url":"https://pubmed.ncbi.nlm.nih.gov/34348265","citation_count":4,"is_preprint":false},{"pmid":"35088877","id":"PMC_35088877","title":"Long noncoding RNA LINC00649 functions as a microRNA‑432‑5p sponge to facilitate tumourigenesis in colorectal cancer by upregulating HDGF.","date":"2022","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/35088877","citation_count":4,"is_preprint":false},{"pmid":"35395072","id":"PMC_35395072","title":"Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/35395072","citation_count":4,"is_preprint":false},{"pmid":"40414865","id":"PMC_40414865","title":"NAP1L1 degradation by FBXW7 reduces the deubiquitination of HDGF-p62 signaling to stimulate autophagy and induce primary cisplatin chemosensitivity in nasopharyngeal carcinoma.","date":"2025","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40414865","citation_count":3,"is_preprint":false},{"pmid":"27926477","id":"PMC_27926477","title":"Intra- or extra-exosomal secretion of HDGF isoforms: the extraordinary function of the HDGF-A N-terminal peptide.","date":"2017","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27926477","citation_count":3,"is_preprint":false},{"pmid":"36694627","id":"PMC_36694627","title":"circ-IARS depletion inhibits the progression of non-small-cell lung cancer by circ-IARS/miR-1252-5p/HDGF ceRNA pathway.","date":"2023","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/36694627","citation_count":3,"is_preprint":false},{"pmid":"18478933","id":"PMC_18478933","title":"[Expression of HDGF and its implication in stage I non-small cell lung cancer].","date":"2007","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/18478933","citation_count":3,"is_preprint":false},{"pmid":"39041204","id":"PMC_39041204","title":"Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39041204","citation_count":2,"is_preprint":false},{"pmid":"40643435","id":"PMC_40643435","title":"Targeting the HNRNPA2B1/HDGF/PTN Axis to Overcome Radioresistance in Non-Small Cell Lung Cancer.","date":"2025","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/40643435","citation_count":1,"is_preprint":false},{"pmid":"37384958","id":"PMC_37384958","title":"Decreased acetylation of HDGF improves oviduct production in Rana dybowskii, Rana amurensis, and Rana huanrenensis.","date":"2023","source":"Comparative biochemistry and physiology. Part D, Genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/37384958","citation_count":1,"is_preprint":false},{"pmid":"32647008","id":"PMC_32647008","title":"Motoneuron expression profiling identifies an association between an axonal splice variant of HDGF-related protein 3 and peripheral myelination.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32647008","citation_count":1,"is_preprint":false},{"pmid":"37920439","id":"PMC_37920439","title":"[Retracted] MicroRNA‑139‑5p inhibits cell viability, migration and invasion and suppresses tumor growth by targeting HDGF in non‑small cell lung cancer.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/37920439","citation_count":1,"is_preprint":false},{"pmid":"40770862","id":"PMC_40770862","title":"HDGF derived from Müller cells enhances the activation of microglia in diabetic retinopathy.","date":"2025","source":"Journal of biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/40770862","citation_count":0,"is_preprint":false},{"pmid":"41462634","id":"PMC_41462634","title":"HDGF Protects Retinal Pigment Epithelium from Glyoxal-Induced Ferroptosis via SIRT1/PGC-1α/Nrf2 Pathway.","date":"2025","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41462634","citation_count":0,"is_preprint":false},{"pmid":"41418975","id":"PMC_41418975","title":"A KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41418975","citation_count":0,"is_preprint":false},{"pmid":"41278276","id":"PMC_41278276","title":"Downregulation of HDGF inhibits tumorigenic phenotypes of hypopharyngeal squamous cell carcinoma by suppressing the AKT/mTOR/VEGF pathway.","date":"2025","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41278276","citation_count":0,"is_preprint":false},{"pmid":"41467359","id":"PMC_41467359","title":"Multi-Omics Analysis Reveals That the MAZ/HDGF Regulatory Axis Drives High-Grade Serous Ovarian Cancer Progression by Modulating Glycolysis and M2 Macrophage Polarization.","date":"2026","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/41467359","citation_count":0,"is_preprint":false},{"pmid":"41234080","id":"PMC_41234080","title":"[CircRAD18 Regulates Daunorubicin Resistance in Acute Myeloid Leukemia Cells through MiR-185-5p/HDGF Axis].","date":"2025","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/41234080","citation_count":0,"is_preprint":false},{"pmid":"42245633","id":"PMC_42245633","title":"Lactylation-driven metabolic reprogramming promotes osteosarcoma malignancy via HDGF-mediated proliferation and immune modulation.","date":"2026","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/42245633","citation_count":0,"is_preprint":false},{"pmid":"42010436","id":"PMC_42010436","title":"Inhibition of circZFX suppresses malignant phenotypes in cholangiocarcinoma via the miR-654-3p/HDGF and YAP1 signaling activation.","date":"2026","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/42010436","citation_count":0,"is_preprint":false},{"pmid":"42171425","id":"PMC_42171425","title":"HDGF as a Novel Serological Marker for Proliferative Diabetic Retinopathy: A Mendelian Randomization and Cross-Sectional Study.","date":"2026","source":"Translational vision science & technology","url":"https://pubmed.ncbi.nlm.nih.gov/42171425","citation_count":0,"is_preprint":false},{"pmid":"34526780","id":"PMC_34526780","title":"Long Non-Coding RNA ASB16-AS1 Functions as a miR-760 Sponge to Facilitate the Malignant Phenotype of Osteosarcoma by Increasing HDGF Expression [Retraction].","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34526780","citation_count":0,"is_preprint":false},{"pmid":"33030654","id":"PMC_33030654","title":"Correction to: A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma.","date":"2020","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33030654","citation_count":0,"is_preprint":false},{"pmid":"34675543","id":"PMC_34675543","title":"MicroRNA-939 Directly Targets HDGF to Inhibit the Aggressiveness of Prostate Cancer via Deactivation of the WNT/β-Catenin Pathway [Retraction].","date":"2021","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34675543","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.04.25329006","title":"Proteomic and genetic insights into ancestry-specific associations in Parkinson’s disease","date":"2025-06-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.04.25329006","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.07.25323594","title":"Proteomics analysis of plasma for risk of sepsis: Findings from the Atherosclerosis Risk in Communities Study","date":"2025-03-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.07.25323594","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49123,"output_tokens":7966,"usd":0.13343,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17399,"output_tokens":7922,"usd":0.142522,"stage2_stop_reason":"end_turn"},"total_usd":0.275952,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"The HDGF PWWP domain (N-terminal ~70 amino acids) was determined to high resolution by NMR using NOEs, J-couplings, and dipolar couplings. NMR titrations and SELEX (SAAB) assays demonstrated that the PWWP domain functions as a nonspecific DNA-binding domain, interacting with DNA via the minor groove.\",\n      \"method\": \"NMR structure determination (NOEs, J-couplings, dipolar couplings); SELEX/SAAB DNA-binding assay; NMR titrations with DNA\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution NMR structure with multiple orthogonal validation methods (dipolar couplings, SAAB, NMR titrations) in a single focused study\",\n      \"pmids\": [\"16384999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tandem affinity purification (SBP/Flag-TAP) coupled with LC-MS/MS identified 106 proteins forming complexes with HDGF, placing it in complexes involved in ribosome biogenesis, RNA processing, DNA damage repair, and transcriptional regulation. The HATH domain was found to be essential for both protein–protein and protein–RNA interactions; deletion of HATH abolished complex formation. RNA co-immunoprecipitation (SBP-RIP) also detected RNA in the HDGF complex.\",\n      \"method\": \"SBP/Flag tandem affinity purification coupled to LC-MS/MS; Co-IP; RT-PCR; RIP assay; domain-deletion analysis\",\n      \"journal\": \"Journal of proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass-spectrometry interactome with domain-deletion validation and RIP, single lab; pan-interactome study but includes specific domain-function mapping for HDGF\",\n      \"pmids\": [\"21907836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"p53 transcriptionally represses HDGF by altering HDAC-dependent chromatin remodeling. Wild-type p53 introduction decreased endogenous HDGF expression; conditioned medium from p53-expressing cells blocked cell growth, migration, and invasion, effects reversible by recombinant HDGF addition. Mechanistic studies showed p53 represses HDGF transcription through chromatin remodeling involving HDACs.\",\n      \"method\": \"p53 overexpression in cancer cells; HDGF neutralizing antibody; recombinant HDGF rescue; chromatin remodeling (HDAC-dependent) mechanistic analysis; Western blot; cell growth and migration assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (p53 introduction) plus pharmacological (HDAC), rescue with recombinant protein, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"22006999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Cell surface heparan sulfates (HS) are required for HDGF internalization. Cells lacking surface HS could not internalize HDGF, its HATH domain, or a receptor-binding-deficient HATH mutant (K96A). Both HATH and HATH(K96A) enter cells via macropinocytosis after binding cell surface HS. HS-mediated internalization of HATH(K96A) inhibited cell migration and proliferation (opposite to HATH), and MAPK signaling pathways were differentially affected by the two constructs, regulating matrix metalloprotease expression in NIH 3T3 fibroblasts.\",\n      \"method\": \"HS-deficient cell lines; macropinocytosis inhibition assays; site-directed mutagenesis (K96A); cell migration/proliferation assays; MAPK pathway analysis; MMP expression analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis combined with HS-deficient cell lines, macropinocytosis assays, and functional readouts in a single focused study demonstrating mechanism\",\n      \"pmids\": [\"20964630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HDGF forms heteromers with HRP-2 isoforms. A newly identified splice variant of HRP-2 (isoform c, with 53-amino acid deletion in the HATH region) preferentially interacts with a processed form of HDGF and, unlike other HRP-2 isoforms, binds to chromatin. HRP-2 isoform c and the processed form of HDGF are both displaced from condensed mitotic metaphase chromatin.\",\n      \"method\": \"Co-immunoprecipitation; chromatin fractionation; identification of splice variant by molecular cloning; mitotic chromatin displacement assay\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus chromatin fractionation, single lab, two orthogonal methods\",\n      \"pmids\": [\"22212508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HDGF undergoes caspase-dependent dephosphorylation during the early steps of TNF+cycloheximide-induced apoptosis in endothelial cells, prior to mitochondrial membrane permeabilization. This event was blocked by the pan-caspase inhibitor zVADfmk, placing HDGF dephosphorylation downstream of an initiator caspase. Nuclear localization of GFP-HDGF was unaffected by the apoptotic stimulus.\",\n      \"method\": \"2D gel electrophoresis of 32P-labeled samples; mass spectrometry identification; Western blot; zVADfmk caspase inhibition; GFP-HDGF live-cell imaging\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic identification plus pharmacological (caspase inhibitor) epistasis, GFP imaging, single lab\",\n      \"pmids\": [\"18465786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NMR H2CN titration experiments identified lysine K19 as the key residue in HDGF mediating electrostatic interaction with heparin, with side-chain chemical shift perturbations correlating with binding free energy changes in site-directed mutants. Backbone chemical shifts did not reliably report on heparin binding at this buried residue.\",\n      \"method\": \"H2CN NMR pulse sequence; heparin titration; site-directed mutagenesis; free energy correlation analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro NMR with mutagenesis and free energy correlation, single lab with multiple orthogonal NMR methods\",\n      \"pmids\": [\"25117899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDGF forms a complex with DDX5 and β-catenin. Co-immunoprecipitation combined with mass spectrometry and GST pull-down demonstrated that DDX5 directly interacts with HDGF, and HDGF/DDX5 induces β-catenin–c-Myc signaling, which suppresses miR-296-3p expression in lung adenocarcinoma cells. ChIP and EMSA assays further characterized the DNA-protein interactions in this pathway.\",\n      \"method\": \"Co-immunoprecipitation combined with mass spectrometry; GST pull-down; ChIP; EMSA; Western blot; luciferase reporter assay\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus MS and GST pull-down for direct interaction, ChIP/EMSA for functional context, single lab\",\n      \"pmids\": [\"28751441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZEB1 transcription factor binds to the HDGF promoter to stimulate HDGF transcription, and ZEB1 also physically interacts with HDGF protein and co-localizes with it in the nucleus. HDGF in turn activates β-catenin/TCF4 signaling, which feeds back to stimulate ZEB1 transcription, creating a ZEB1/HDGF/β-catenin/TCF4 positive feedback loop promoting endometrial cancer metastasis.\",\n      \"method\": \"ChIP assay (ZEB1 promoter binding); co-immunoprecipitation (ZEB1–HDGF interaction); immunofluorescence co-localization; siRNA knockdown; β-catenin nuclear translocation assay; in vitro and in vivo functional assays\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus nuclear translocation assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31815037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDGF drives Ewing sarcoma (ES) metastasis by functioning as a transcription factor. ChIP-seq and gene expression profiling revealed that HDGF directly regulates the ALCAM gene, repressing its expression. HDGF downregulation of ALCAM induces expression and activation of Rho-GTPases Rac1 and Cdc42, promoting actin cytoskeleton remodeling and cell-matrix adhesion to enhance metastasis. Repression of ALCAM and activation of Rac1/Cdc42 are required for HDGF's pro-metastatic functions.\",\n      \"method\": \"HDGF ChIP-seq; gene expression profiling; siRNA/shRNA knockdown; Rac1/Cdc42 activation assays; actin cytoskeleton imaging; orthotopic mouse model; experimental metastasis model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq plus expression profiling plus functional in vitro and in vivo validation with multiple mechanistic readouts, single lab but comprehensive\",\n      \"pmids\": [\"33239755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NAP1L1 interacts with HDGF at the protein level and co-localizes with it in the cytoplasm. HDGF in turn interacts with the transcription factor c-Jun, which induces expression of cell-cycle promoters CCND1/CDK4/CDK6. HDGF knockdown in NAP1L1-overexpressing glioma cells inhibits proliferation, establishing a NAP1L1→HDGF→c-Jun→CCND1/CDK4/CDK6 signaling axis.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence co-localization; siRNA knockdown; Western blot; in vitro and in vivo proliferation assays\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus immunofluorescence co-localization plus rescue experiments, single lab\",\n      \"pmids\": [\"34959221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NAP1L1 interacts with HDGF and co-localizes in the cytoplasm of ovarian cancer cells. HDGF interacts with c-Jun (C-JUN), which then induces CCND1 expression to promote cell proliferation. HDGF overexpression in NAP1L1-knockdown OC cells restores C-JUN and CCND1 expression and reverses the anti-proliferative effects, confirming HDGF acts downstream of NAP1L1 through HDGF/C-JUN signaling.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence; siRNA and shRNA knockdown; Western blot; CCK-8; EDU assay; flow cytometry; colony formation assay\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus co-localization plus rescue experiments, single lab, replicates findings from PMID:34959221 in a different cancer type\",\n      \"pmids\": [\"35351053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"G3BP2 binds to HDGF mRNA transcripts to stabilize HDGF expression. RNA-seq in ESCC cells revealed HDGF as regulated by G3BP2, and G3BP2 depletion reduced HDGF protein levels. Ectopic HDGF expression rescued G3BP2-depletion-mediated inhibition of ESCC cell migration, placing G3BP2-mediated HDGF mRNA stabilization in the LINC01554/G3BP2/HDGF regulatory axis.\",\n      \"method\": \"RNA-seq; Western blot; qRT-PCR; rescue overexpression experiments; in vitro migration assays; in vivo xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq plus rescue experiments identifying post-transcriptional regulation mechanism, single lab\",\n      \"pmids\": [\"34782720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL3-mediated N6-methyladenosine (m6A) RNA methylation of HDGF mRNA enhances its mRNA stability and protein expression in M1 macrophages during atherosclerosis. Elevated METTL3 in M1 macrophages increases HDGF protein via m6A modification; HDGF in turn regulates M1 macrophage polarization through energy metabolism reprogramming (glycolysis, mitochondrial function), contributing to atherosclerotic plaque formation.\",\n      \"method\": \"m6A RNA methylation analysis; macrophage-specific HDGF knockout mouse (ApoeKO model); Western blot; metabolic assays (glycolysis, mitochondria); in vivo plaque quantification\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A modification with in vivo KO model and metabolic readouts, single lab\",\n      \"pmids\": [\"36265285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HDGF stimulates mitochondrial reactive oxygen species (ROS) generation and upregulates oxidative phosphorylation and bioenergetics in hepatoma cells (increased basal and total oxygen consumption rate, extracellular acidification rate). This is mediated through the HDGF receptor nucleolin (NCL) on the cell surface: genetic knockdown of NCL and anti-NCL antibody abolished HDGF-induced ROS and mitochondrial energetic increases. An inactive Ser103Ala mutant of recombinant HDGF failed to promote ROS generation or oncogenic behaviors.\",\n      \"method\": \"Recombinant HDGF treatment; Ser103Ala mutagenesis; Seahorse metabolic flux assay; ROS-detecting fluorescent dyes; flow cytometry; NCL knockdown (siRNA); anti-NCL antibody neutralization; MitoQ/NAC antioxidant treatment; SOD2 knockdown; in vivo orthotopic hepatoma model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant protein, active-site mutagenesis (Ser103Ala), receptor identification with antibody neutralization and siRNA, Seahorse metabolic profiling; multiple orthogonal methods in single study\",\n      \"pmids\": [\"37827291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HDGF promotes gefitinib resistance in NSCLC by activating the PI3K/AKT and MEK/ERK signaling pathways independently of EGFR phosphorylation. Gefitinib treatment induced HDGF expression; effects of HDGF on gefitinib resistance were largely attenuated by the AKT inhibitor MK2206 or the ERK inhibitor U0126, establishing epistatic placement of HDGF upstream of these pathways.\",\n      \"method\": \"Stable HDGF KO and overexpression cell lines; AKT inhibitor (MK2206); ERK inhibitor (U0126); ELISA; Western blot; in vitro and in vivo drug resistance assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO/OE with pharmacological epistasis (two independent pathway inhibitors), single lab\",\n      \"pmids\": [\"37301856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HDGF modulates DNA damage response by recruiting CtIP (C-terminal binding protein-interacting protein) to facilitate homologous recombination (HR) repair, thereby influencing drug sensitivity in colorectal cancer. HDGF is proposed to function as a recognition protein for H3K36me3, participating in the repair of transcriptionally active damaged genes to maintain genomic stability.\",\n      \"method\": \"HDGF knockout cells; CtIP interaction/recruitment assays; HR repair assays; drug sensitivity assays; Western blot\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — CtIP recruitment and HR assays described but limited methodological detail in abstract; single lab, single study\",\n      \"pmids\": [\"40001585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The m6A reader IGF2BP2 binds to and stabilizes HDGF mRNA transcripts in an m6A-dependent manner in esophageal squamous cell carcinoma (ESCC), promoting HDGF protein expression and ESCC proliferation, migration, invasion, and tumorigenicity.\",\n      \"method\": \"m6A-dependent RNA binding assays (IGF2BP2–HDGF mRNA); siRNA/overexpression; in vitro proliferation/migration/invasion assays; in vivo tumorigenicity\",\n      \"journal\": \"Journal of cancer research and therapeutics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — binding interaction described but limited mechanistic detail in abstract; single lab\",\n      \"pmids\": [\"39206979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In ovarian cancer cells, HDGF localizes predominantly in the nucleus but is minimally secreted under normal conditions. However, HDGF is passively released by necrotic and late apoptotic cells. Extracellular HDGF stimulates phosphorylation of ERK1/2 and p38 MAPK and enhances cellular migration in both cancer and non-cancer cells, suggesting HDGF functions as an alarmin.\",\n      \"method\": \"Immunofluorescence (nuclear localization); conditioned media analysis; necrosis/apoptosis induction assays; ERK1/2 and p38 phosphorylation assays (Western blot); cell migration assays\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by immunofluorescence with functional consequence (ERK/p38 signaling, migration), single lab, two orthogonal methods\",\n      \"pmids\": [\"26612514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Subcellular localization of HDGF was determined experimentally in cultured neocortical neurons: HDGF is restricted to the neuronal soma and is present in both nucleus and cytoplasm, while the related HRP-3 can additionally be found in neurites. Simultaneous expression in the same cell with different subcellular distributions suggests different intracellular functions for HDGF and HRP-3.\",\n      \"method\": \"Immunocytochemistry; in situ hybridization; immunohistochemistry; generation of isoform-specific antisera\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct immunocytochemistry-based localization with isoform-specific antisera in primary cultures, single lab\",\n      \"pmids\": [\"14572309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HDGF secreted by glioblastoma stem-like cells (GSCs) functions as a pro-angiogenic factor. Anti-HDGF antibodies blocked GSC-conditioned medium-induced migration of cerebral endothelial cells. In vivo, GSC-conditioned medium induced neoangiogenesis, and HDGF-targeting siRNAs abrogated this effect.\",\n      \"method\": \"Proteomic 2D-DIGE and MS identification; anti-HDGF antibody neutralization; endothelial cell migration assay; in vivo Matrigel neoangiogenesis model; HDGF siRNA knockdown\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization plus siRNA with in vivo angiogenesis assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"22331796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Hepatocellular carcinoma cell-derived HDGF induces generation of Foxp3+ regulatory T cells (Tregs) from CD4+CD25- T cells. Exposure to recombinant HDGF increased Foxp3 expression and decreased GATA3 expression in CD4+ T cells. The induced Tregs suppressed CD8+ T cell proliferation and cytotoxic cytokine release, linking HDGF to immune evasion.\",\n      \"method\": \"HDGF expression by qRT-PCR and Western blot; co-culture of hepatoma cells with CD4+CD25- T cells; flow cytometry for Foxp3; CFSE-dilution assay for CD8+ suppression; ELISA for cytokines\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — recombinant protein treatment with functional T cell assays, flow cytometry, CFSE suppression assay; single lab\",\n      \"pmids\": [\"25569374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HDGF functions as an angiogenic factor that enhances VEGF-dependent angiogenesis in EBC-1 NSCLC cells (but not in Lu99 cells). Tube formation, neutralization, and RNA interference assays using both standard and novel 3D collagen-gel culture supernatants demonstrated that HDGF and VEGF-A cooperate in angiogenesis in a cell-line-dependent manner.\",\n      \"method\": \"Mass spectrometry protein identification from serum-free conditioned medium; endothelial tube formation assay; neutralizing antibody; siRNA knockdown; 3D collagen gel culture; gene microarray\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization plus siRNA in two independent culture systems (standard and 3D), single lab\",\n      \"pmids\": [\"32319650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HDGF is present inside extracellular vesicles (EVs) released by multiple myeloma cells and activates AKT phosphorylation in myeloma cells when added exogenously. HDGF also enhances glycolysis and reduces mitochondrial respiration in myeloma cells, and polarizes macrophages toward an M1-like phenotype while altering monocytes to resemble myeloid-derived suppressor cells.\",\n      \"method\": \"EV proteomic analysis; HDGF knockdown (proliferation assay); exogenous HDGF addition (AKT phosphorylation); Seahorse metabolic analysis; macrophage polarization assays; flow cytometry\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EV proteomics plus functional assays (AKT, Seahorse, macrophage polarization), single lab, multiple readouts\",\n      \"pmids\": [\"35395072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HDGF activates KRAS transcription and suppresses RhoA transcription in prostate cancer cells; these transcriptional effects are mediated in part through HDGF's direct interaction with the helicase BLM. BLM co-immunoprecipitates with HDGF, and BLM depletion modulates HDGF-dependent effects on KRAS and RhoA, consequently activating the MAPK/ERK pathway.\",\n      \"method\": \"Co-immunoprecipitation (BLM–HDGF); ChIP-seq; dual-luciferase reporter assay; Western blot; in vitro functional assays (proliferation, migration, invasion); in vivo xenograft\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP-seq plus luciferase reporter, single lab\",\n      \"pmids\": [\"36574142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FBXW7 E3 ubiquitin ligase directly interacts with and ubiquitinates NAP1L1, targeting it for proteasomal degradation. Reduced NAP1L1 impairs recruitment of the deubiquitinase USP14, limiting deubiquitination of HDGF and thus decreasing HDGF protein levels. In turn, reduced HDGF suppresses USP14-mediated deubiquitination of p62, decreasing p62 levels, and this HDGF/p62 signaling reduction triggers autophagy and enhances cisplatin sensitivity in NPC.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; USP14 deubiquitination assay; Western blot; autophagosome formation assays; in vitro and in vivo NPC models; shRNA knockdown\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination/deubiquitination assays with functional in vivo NPC model, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"40414865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDGF overexpression in NSCLC cells upregulates IL-4 expression in a dose-dependent manner. Secreted HDGF induces macrophage polarization toward the M2 phenotype through the IL-4/JAK1/STAT3 signaling pathway, thereby creating a pro-tumorigenic paracrine loop between NSCLC cells and tumor-associated macrophages.\",\n      \"method\": \"HDGF overexpression constructs; RNA-seq in HDGF-overexpressing cells; IL-4 ELISA; Western blot for JAK1/STAT3; flow cytometry for macrophage markers; co-culture assays; in vivo C57BL/6 tumor model with MTE treatment\",\n      \"journal\": \"Journal of ethnopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq plus ELISA plus Western blot with in vivo validation, single lab\",\n      \"pmids\": [\"35973634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HDGF activates the SIRT1/PGC-1α/Nrf2 pathway and the p38 MAPK/AKT axis in retinal pigment epithelial cells, protecting against glyoxal-induced ferroptosis by restoring mitochondrial biogenesis (MFN2, PGC-1α, SIRT1), enhancing the glutathione/GPX4 antioxidant system, and suppressing lipid peroxidation.\",\n      \"method\": \"Recombinant HDGF treatment; Western blot for pathway components; ROS/lipid peroxidation assays; glutathione measurement; mitochondrial morphology assessment\",\n      \"journal\": \"Antioxidants\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — recombinant protein treatment with pathway readouts, single study, limited mechanistic depth in abstract\",\n      \"pmids\": [\"41462634\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HDGF is a multifunctional heparin-binding nuclear protein whose N-terminal PWWP/HATH domain mediates nonspecific DNA binding and is required for protein–protein and protein–RNA interactions; it is internalized via heparan sulfate-dependent macropinocytosis, undergoes caspase-dependent dephosphorylation during apoptosis and Mettl3/m6A-dependent mRNA stabilization, acts as a transcription factor (e.g., repressing ALCAM in Ewing sarcoma downstream of its direct binding to target chromatin) and a signaling ligand that, upon binding its cell-surface receptor nucleolin, stimulates mitochondrial ROS generation and activates PI3K/AKT and MAPK/ERK pathways; its expression is negatively regulated by p53 through HDAC-dependent chromatin remodeling, and it participates in complexes with DDX5/β-catenin, NAP1L1, ZEB1, BLM, and HRP-2 isoforms to regulate cell cycle progression, EMT, angiogenesis, immune modulation, and drug resistance across multiple cancer contexts.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HDGF is a heparin-binding nuclear protein that functions both as a chromatin-associated transcriptional regulator and as a secreted signaling ligand, contributing to proliferation, metastasis, angiogenesis, immune modulation, and drug resistance across multiple cancers [#9, #14]. Its N-terminal PWWP/HATH domain is a high-resolution-defined fold that binds DNA nonspecifically through the minor groove and is essential for HDGF's protein-protein and protein-RNA interactions, with surface lysine residues (K19) mediating electrostatic engagement of heparin [#0, #1, #6]. Cell-surface heparan sulfate is required for HDGF uptake, and HDGF and its HATH domain are internalized via macropinocytosis, with differential effects on migration, proliferation, and MAPK signaling depending on receptor-binding competence [#3]. As a transcription factor, HDGF binds target chromatin directly to repress ALCAM in Ewing sarcoma, thereby activating Rac1/Cdc42 to drive cytoskeletal remodeling and metastasis, and it also transcriptionally regulates KRAS and RhoA through its interaction with the BLM helicase [#9, #24]. As an extracellular ligand released by necrotic and late apoptotic cells, HDGF stimulates ERK1/2 and p38 MAPK and acts through its cell-surface receptor nucleolin to drive mitochondrial ROS generation and bioenergetic reprogramming, an activity abolished by the Ser103Ala mutation [#18, #14]. HDGF participates in numerous oncogenic protein complexes—with DDX5/\\u03b2-catenin, ZEB1, NAP1L1/c-Jun, and HRP-2 isoforms—coupling it to \\u03b2-catenin, cell-cycle, and EMT programs [#7, #8, #10, #4]. HDGF expression is controlled at multiple levels: p53 represses it via HDAC-dependent chromatin remodeling, m6A readers and RNA-binding proteins (METTL3, IGF2BP2, G3BP2) stabilize its mRNA, and a USP14-dependent deubiquitination cascade controls its protein stability [#2, #13, #12, #25]. It further shapes the tumor microenvironment by promoting Treg induction, M2 macrophage polarization, and VEGF-dependent angiogenesis [#21, #26, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"The structural basis for HDGF's DNA association was unknown; defining the PWWP/HATH fold established it as a nonspecific minor-groove DNA-binding module.\",\n      \"evidence\": \"High-resolution NMR structure with SELEX/SAAB DNA-binding assays and NMR titrations\",\n      \"pmids\": [\"16384999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No sequence-specific DNA recognition demonstrated\", \"Does not address how nonspecific DNA binding relates to gene-specific transcriptional regulation\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Whether HDGF acts within larger macromolecular assemblies was unclear; interactome mapping placed it in ribosome biogenesis, RNA processing, DNA repair, and transcription complexes and showed the HATH domain is essential for both protein and RNA interactions.\",\n      \"evidence\": \"Tandem affinity purification with LC-MS/MS, Co-IP, RIP, and domain-deletion analysis\",\n      \"pmids\": [\"21907836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect interactions not resolved for most of the 106 proteins\", \"Functional consequence of each complex not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The upstream regulation of HDGF was uncharacterized; p53 was shown to repress HDGF transcription via HDAC-dependent chromatin remodeling, linking HDGF to tumor suppressor control.\",\n      \"evidence\": \"p53 overexpression, HDAC mechanistic analysis, recombinant HDGF rescue of conditioned-medium effects\",\n      \"pmids\": [\"22006999\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct p53 binding to the HDGF promoter not shown\", \"Specific HDAC enzymes not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"How extracellular HDGF enters cells was unknown; heparan sulfate-dependent macropinocytosis was established as the uptake route, with receptor-binding competence dictating opposing effects on cell behavior.\",\n      \"evidence\": \"HS-deficient cell lines, K96A mutagenesis, macropinocytosis inhibition, MAPK and MMP readouts in fibroblasts\",\n      \"pmids\": [\"20964630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The signaling receptor distinct from HS not identified in this study\", \"Intracellular fate after internalization unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Whether HDGF is post-translationally modified during cell death was unknown; caspase-dependent dephosphorylation was placed early in apoptosis, before mitochondrial permeabilization.\",\n      \"evidence\": \"32P-labeling 2D gels, MS, zVADfmk caspase inhibition, GFP-HDGF imaging in endothelial cells\",\n      \"pmids\": [\"18465786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The phosphatase responsible not identified\", \"Functional consequence of dephosphorylation not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The relationship between HDGF and its HRP-2 paralog isoforms was unclear; a HATH-truncated HRP-2 splice variant was shown to preferentially bind a processed HDGF form and associate with chromatin, both displaced from mitotic chromatin.\",\n      \"evidence\": \"Reciprocal Co-IP, chromatin fractionation, molecular cloning, mitotic displacement assay\",\n      \"pmids\": [\"22212508\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nature of the processed HDGF form not defined\", \"Functional role of cell-cycle chromatin displacement unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The molecular determinant of HDGF's heparin binding was uncharacterized; K19 was identified as the key electrostatic contact residue using side-chain-specific NMR.\",\n      \"evidence\": \"H2CN NMR pulse sequence, heparin titration, mutagenesis, binding free-energy correlation\",\n      \"pmids\": [\"25117899\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of K19 to HS-dependent uptake not tested\", \"Whether heparin binding modulates signaling not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"It was unknown whether secreted HDGF drives tumor vascularization; glioblastoma stem-cell-derived HDGF was shown to act as a pro-angiogenic factor.\",\n      \"evidence\": \"2D-DIGE/MS identification, anti-HDGF neutralization, endothelial migration, in vivo Matrigel neoangiogenesis, siRNA\",\n      \"pmids\": [\"22331796\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor on endothelial cells not identified\", \"Relationship to VEGF not addressed in this study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The immunomodulatory role of HDGF was undefined; hepatoma-derived HDGF was shown to induce Foxp3+ Tregs that suppress CD8+ T cells, implicating it in immune evasion.\",\n      \"evidence\": \"Recombinant HDGF treatment, Foxp3 flow cytometry, CFSE suppression assay, cytokine ELISA\",\n      \"pmids\": [\"25569374\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/signaling pathway in T cells not identified\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"How HDGF reaches the extracellular space was unclear; it was shown to be predominantly nuclear and passively released by necrotic/late apoptotic cells, acting as an alarmin via ERK1/2 and p38.\",\n      \"evidence\": \"Immunofluorescence, conditioned media, necrosis/apoptosis induction, MAPK phosphorylation, migration assays\",\n      \"pmids\": [\"26612514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No active secretion mechanism defined\", \"Receptor mediating ERK/p38 activation not identified here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"HDGF's coupling to Wnt signaling was unknown; a direct DDX5-HDGF complex was shown to drive \\u03b2-catenin/c-Myc signaling and suppress miR-296-3p in lung adenocarcinoma.\",\n      \"evidence\": \"Co-IP/MS, GST pull-down, ChIP, EMSA, luciferase reporter\",\n      \"pmids\": [\"28751441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and direct DNA-binding role of HDGF in this complex unclear\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The interplay between HDGF and EMT regulators was undefined; a ZEB1/HDGF/\\u03b2-catenin/TCF4 positive feedback loop was established in endometrial cancer.\",\n      \"evidence\": \"ChIP, Co-IP, immunofluorescence co-localization, siRNA, in vivo assays\",\n      \"pmids\": [\"31815037\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. cofactor role of HDGF at ZEB1-regulated promoters not resolved\", \"Single cancer type\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"HDGF's effect on tumor macrophages was unknown; secreted HDGF was shown to drive M2 polarization via the IL-4/JAK1/STAT3 axis in NSCLC.\",\n      \"evidence\": \"Overexpression, RNA-seq, IL-4 ELISA, JAK1/STAT3 Western blot, co-culture, in vivo model\",\n      \"pmids\": [\"35973634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor for HDGF on macrophages not identified\", \"Mechanism of IL-4 induction by HDGF unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Whether HDGF directly programs metastatic gene expression was open; ChIP-seq showed HDGF directly represses ALCAM, activating Rac1/Cdc42 to drive Ewing sarcoma metastasis.\",\n      \"evidence\": \"HDGF ChIP-seq, expression profiling, knockdown, Rac1/Cdc42 activation assays, orthotopic and metastasis mouse models\",\n      \"pmids\": [\"33239755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide direct target set beyond ALCAM not fully resolved\", \"Cofactors at the ALCAM locus not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The relationship between HDGF and canonical angiogenic factors was unclear; HDGF was shown to cooperate with VEGF-A in a cell-line-dependent manner to enhance angiogenesis.\",\n      \"evidence\": \"MS identification, tube formation, neutralizing antibody, siRNA, 3D collagen-gel culture, microarray\",\n      \"pmids\": [\"32319650\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis for cell-line dependence unexplained\", \"Molecular link between HDGF and VEGF not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"How HDGF cooperates with chromatin factors to control oncogenes was unknown; a direct HDGF-BLM interaction was shown to activate KRAS and repress RhoA transcription, feeding MAPK/ERK signaling in prostate cancer.\",\n      \"evidence\": \"Co-IP, ChIP-seq, dual-luciferase reporter, in vitro and in vivo assays\",\n      \"pmids\": [\"36574142\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA binding of HDGF at KRAS/RhoA loci not separated from BLM contribution\", \"Helicase-dependence not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"An upstream activator of HDGF in proliferation was unknown; NAP1L1 was shown to interact with HDGF, channeling into an HDGF\\u2192c-Jun\\u2192CCND1/CDK4/CDK6 cell-cycle axis in glioma.\",\n      \"evidence\": \"Co-IP, immunofluorescence co-localization, siRNA, proliferation assays in vitro and in vivo\",\n      \"pmids\": [\"34959221\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect NAP1L1-HDGF binding not resolved\", \"How HDGF activates c-Jun not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Generality of the NAP1L1/HDGF/c-Jun axis was uncertain; the same axis was confirmed in ovarian cancer with HDGF acting downstream of NAP1L1 to restore C-JUN and CCND1.\",\n      \"evidence\": \"Co-IP, immunofluorescence, knockdown/rescue, proliferation and cell-cycle assays\",\n      \"pmids\": [\"35351053\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism unchanged from prior study; direct interaction nature still unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-transcriptional control of HDGF was undefined; G3BP2 was shown to bind and stabilize HDGF mRNA within a LINC01554/G3BP2/HDGF axis driving ESCC migration.\",\n      \"evidence\": \"RNA-seq, qRT-PCR, Western blot, rescue overexpression, migration and xenograft assays\",\n      \"pmids\": [\"34782720\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct G3BP2-HDGF mRNA binding sites not mapped\", \"Relation to m6A regulation not addressed here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Whether m6A modification controls HDGF was unknown; METTL3-mediated m6A was shown to stabilize HDGF mRNA in M1 macrophages, with HDGF reprogramming energy metabolism in atherosclerosis.\",\n      \"evidence\": \"m6A analysis, macrophage-specific HDGF KO ApoeKO mice, metabolic assays, plaque quantification\",\n      \"pmids\": [\"36265285\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A reader linking METTL3 to HDGF stability not identified here\", \"Direct metabolic targets of HDGF unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Whether HDGF travels in vesicles and signals metabolically was open; HDGF was found in myeloma extracellular vesicles and shown to activate AKT, shift glycolysis, and polarize immune cells.\",\n      \"evidence\": \"EV proteomics, exogenous HDGF treatment, AKT phosphorylation, Seahorse, macrophage/monocyte assays\",\n      \"pmids\": [\"35395072\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating EV-HDGF AKT activation not identified\", \"Mechanism of metabolic shift unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The cell-surface receptor for HDGF signaling and its bioenergetic mechanism were unknown; nucleolin was identified as the HDGF receptor mediating mitochondrial ROS and OXPHOS upregulation, with Ser103 required for activity.\",\n      \"evidence\": \"Recombinant HDGF, Ser103Ala mutant, Seahorse, ROS assays, NCL knockdown and antibody neutralization, antioxidant treatment, orthotopic hepatoma model\",\n      \"pmids\": [\"37827291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nucleolin transduces signal to mitochondria not defined\", \"Role of Ser103 phosphorylation status not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"HDGF's contribution to targeted-therapy resistance was unclear; it was shown to confer gefitinib resistance in NSCLC by activating PI3K/AKT and MEK/ERK independently of EGFR.\",\n      \"evidence\": \"Stable KO/OE lines, MK2206 and U0126 pathway inhibitors, ELISA, in vitro and in vivo drug-resistance assays\",\n      \"pmids\": [\"37301856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which HDGF activates these kinases not defined\", \"Link to nucleolin signaling not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Whether an m6A reader stabilizes HDGF mRNA was open; IGF2BP2 was shown to bind and stabilize HDGF mRNA in an m6A-dependent manner in ESCC.\",\n      \"evidence\": \"m6A-dependent RNA binding assays, knockdown/overexpression, proliferation/migration/invasion and tumorigenicity assays\",\n      \"pmids\": [\"39206979\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Limited mechanistic detail in abstract; m6A sites not mapped\", \"Relationship to METTL3/G3BP2 regulation unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A proteostatic mechanism controlling HDGF was unknown; an FBXW7\\u2192NAP1L1\\u2192USP14 cascade was shown to govern HDGF deubiquitination, with HDGF/p62 signaling regulating autophagy and cisplatin sensitivity in NPC.\",\n      \"evidence\": \"Co-IP, ubiquitination/deubiquitination assays, autophagosome assays, in vitro and in vivo NPC models, shRNA\",\n      \"pmids\": [\"40414865\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct USP14-HDGF deubiquitination not fully isolated from NAP1L1 dependence\", \"Ubiquitin chain type on HDGF not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A potential role for HDGF in chromatin-coupled DNA repair was proposed; HDGF was suggested to read H3K36me3 and recruit CtIP to facilitate homologous recombination in colorectal cancer.\",\n      \"evidence\": \"HDGF KO cells, CtIP recruitment and HR repair assays, drug-sensitivity assays\",\n      \"pmids\": [\"40001585\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"H3K36me3 recognition not directly demonstrated\", \"Direct HDGF-CtIP interaction not confirmed with limited detail\", \"Mechanism of HR facilitation unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A cytoprotective role for HDGF outside cancer was proposed; recombinant HDGF was shown to protect retinal pigment epithelium from ferroptosis via SIRT1/PGC-1\\u03b1/Nrf2 and p38 MAPK/AKT.\",\n      \"evidence\": \"Recombinant HDGF treatment, pathway Western blots, ROS/lipid peroxidation and glutathione assays, mitochondrial morphology\",\n      \"pmids\": [\"41462634\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Receptor and direct mechanism not defined\", \"Single study with limited mechanistic depth\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HDGF's nuclear chromatin-regulatory functions are mechanistically linked to its extracellular nucleolin-mediated signaling, and whether a single histone-mark reader activity unifies its transcription and DNA-repair roles, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of the secreted ligand-nucleolin complex\", \"Histone-mark reading by the PWWP domain not directly demonstrated in human HDGF\", \"Whether nuclear and extracellular pools represent distinct functional states is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [9, 24]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [14, 18]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [18, 19, 4]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 11, 19]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [18, 20, 22]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 14]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [9, 24]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [21, 26]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 15, 25]}\n    ],\n    \"complexes\": [\"HDGF-DDX5-\\u03b2-catenin complex\", \"HDGF-HRP-2 heteromer\"],\n    \"partners\": [\"NCL\", \"DDX5\", \"ZEB1\", \"NAP1L1\", \"BLM\", \"CtIP\", \"HRP-2\", \"CTNNB1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}